Chief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the MoonLake Immunotherapeutics (NASDAQ:MLTX) Chief Financial Officer, Matthias Bodenstedt, recently bought US$99k worth of stock, for US$9.09 per share. However, it only increased their shares held by 1.8%, and it wasn't a huge purchase by absolute value, either.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

MoonLake Immunotherapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by Matthias Bodenstedt is the biggest insider purchase of MoonLake Immunotherapeutics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$9.89. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for MoonLake Immunotherapeutics share holders is that an insider was buying at near the current price. Matthias Bodenstedt was the only individual insider to buy during the last year.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for MoonLake Immunotherapeutics

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership Of MoonLake Immunotherapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that MoonLake Immunotherapeutics insiders own 11% of the company, worth about US$72m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Do The MoonLake Immunotherapeutics Insider Transactions Indicate?

The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of MoonLake Immunotherapeutics we think they are probably pretty confident of a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 3 warning signs for MoonLake Immunotherapeutics (2 are a bit concerning!) and we strongly recommend you look at them before investing.

Of course MoonLake Immunotherapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.